Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TT-702 |
| Trade Name | |
| Synonyms | TT 702|TT702 |
| Drug Descriptions |
TT-702 is an antagonist of the A2B (ADORA2B) receptor that inhibits agonist-stimulated cAMP production, potentially leading to decreased tumor fibrosis and angiogenesis, enhanced antitumor immune response, and decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 55). |
| DrugClasses | Adenosine Targeting 24 |
| CAS Registry Number | NA |
| NCIT ID | C187108 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Darolutamide + TT-702 | Darolutamide TT-702 | 0 | 1 |
| Enzalutamide + TT-702 | Enzalutamide TT-702 | 0 | 0 |
| TT-702 | TT-702 | 0 | 1 |
| TT-702 + unspecified PD-1 antibody | TT-702 unspecified PD-1 antibody | 0 | 0 |